FDA panel endorses Medtronic Revo MRI pacemaker
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is on track to be the first to market a pacemaker labeled for safe use with magnetic resonance imaging procedures in the U.S. following a unanimous 15-0 approval recommendation from FDA's Circulatory System Devices advisory panel March 19. The panel conditioned its approval recommendation on a post-market study to further evaluate what happens on multiple MRI scans over time, and to capture more data on the device's lead system. The advisory group also seeks training for radiology technicians who perform MRI scans so that they can identify patients with the devices and meet related scan requirements. Device labeling also should specify that the system is only MRI-safe with the appropriate pacer and lead combination, the panel said. "The results were what we needed to see" to justify FDA approval, said panel member David Naftel, Ph.D., University of Alabama, Birmingham
You may also be interested in...
Medtronic Hopes For Speedy U.S. Launch Of Revo MRI-Friendly Pacer
Medtronic is hoping to receive FDA approval of its Revo MRI SureScan MRI-safe pacemaker and launch it in the U.S. within six months now that the device has received a unanimous approval recommendation from an FDA advisory panel
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.